News | Heart Valve Technology | February 18, 2025

New Treatment Options Available for Patients with Tricuspid Valve Disease

Studies involving Cedars-Sinai show minimally invasive procedures can be effective treatments for patients unable to undergo open-heart surgery.

In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. Image by Getty.


Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease..

Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heart surgery and only when absolutely necessary; such surgeries are complex and risky. Now, an increasing number of studies show that cardiac interventionalists can successfully use minimally invasive catheter-based techniques. Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery.

Raj Makkar, MD, vice president of Cardiovascular Innovation and Intervention and the director of the Karsh Division of Interventional Cardiology in the Smidt Heart Institute at Cedars-Sinai, and his team of experts treat more than 10,000 patients every year. Makkar explained the advances for patients with tricuspid valve disease in a conversation with the Cedars-Sinai Newsroom.

CSN: What is tricuspid regurgitation, and who does it affect?

Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium. Studies estimate that severe regurgitation occurs in up to 4% of individuals 75 and older and is often linked with conditions like heart failure, atrial fibrillation or pulmonary hypertension. Women are more frequently affected, and because the condition often develops slowly, many patients are diagnosed at advanced stages when symptoms like swelling, fatigue and breathlessness impact them.

How has treatment for tricuspid valve disease evolved?

Makkar: For decades, tricuspid regurgitation was largely overlooked, often addressed only during surgeries for other heart valves. Today, advances in minimally invasive treatments like transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) are providing new hope. These innovative procedures offer safe and effective options for high-risk patients who previously had limited or no treatment alternatives, focusing on enhancing quality of life.

Cedars-Sinai investigators, in collaboration with colleagues from other leading institutions, recently conducted a clinical trial involving patients with severe tricuspid regurgitation. The study, published in the New England Journal of Medicine, found that patients who underwent catheter-based tricuspid valve replacement combined with medical therapy reported significantly greater improvements in symptoms and quality of life compared with those receiving medical therapy alone. These findings mark a significant step forward in the treatment of this historically neglected condition.

When might a minimally invasive procedure be the best approach?

Makkar: Minimally invasive procedures for the tricuspid valve are generally the only option for older or frail patients, who are unable to withstand traditional open-heart surgery. A TEER procedure, which inserts clips in the valve to reduce leakage, works well for many, but is less effective for those with complex valve anatomy. In such cases, TTVR, which replaces the valve entirely, may be a better option.

How do you discuss options with patients?

Makkar: At the Smidt Heart Institute, physicians discuss the case as a group and review imaging findings and other information to determine whether a transcatheter procedure, minimally invasive surgery, medical intervention alone or a clinical trial is best for each patient.

Selecting the right treatment involves careful evaluation of the patient’s health, anatomy and goals. We prioritize improving quality of life, particularly for patients experiencing severe fatigue and breathlessness.

 

 

Disclosures: Dr. Makkar reports research grants from Edwards Lifesciences, Abbott Vascular, Boston Scientific, JenaValve and Medtronic; he has received travel support from Edwards Lifesciences, JenaValve, Abbott Vascular and Boston Scientific.

 


Related Content

News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
News | Heart Valve Technology

Jan. 6, 2025 — Medtronic plc has announced it received CE (Conformité Européenne) Mark for the Harmony Transcatheter ...

Home January 06, 2025
Home
News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
Subscribe Now